Johns Hopkins adopts DYSIS Advanced Cervical Imaging – DYSIS Medical

Johns Hopkins adopts DYSIS Advanced Cervical Imaging

Johns Hopkins adopts DYSIS Advanced Cervical Imaging

Edinburgh, U.K. – December 14, 2016 – DYSIS Medical, Ltd. announced today that the Johns Hopkins Department of Gynaecology and Obstetrics became the 100th site to purchase the DYSIS Advanced Cervical Imaging System – a next-generation colposcope with proprietary software tools used to assess women for cancer or pre-cancer of the cervix after an abnormal Pap smear. The DYSIS imaging technology standardises colposcopy and produces an intuitive colour-coded map that assists physicians and residents in identifying, documenting and biopsying abnormal areas of the cervix.

Clinical studies in Europe and the U.S. have demonstrated that when the map is added to a standard exam, detection of high grade disease is substantially increased. An 11,000 patient clinical trial (IMPROVE-COLPO) is being conducted in the U.S. and has already demonstrated superior detection rates in data presented at the 2016 American College of Obstetricians and Gynaecologists Annual Clinical and Scientific Meeting.

DYSIS Medical’s CEO, Alastair Atkinson commented, “I am really delighted that we are working with such an esteemed institution as Johns Hopkins and that they recognise the important clinical contribution that DYSIS can make. The DYSIS system offers significant value, not only to patients, but also to teaching institutions because the digital analytics provide such an enhanced educational experience. We are working closely with a number of teaching hospitals to bring together our hardware and software systems to provide an enriched experience.”


DYSIS Medical, Inc.

Tel: +44 (0) 131 338 6131

Alastair Atkinson


B-Roll available


DYSIS Medical Ltd

DYSIS Medical Ltd has its global headquarters in Edinburgh and US Headquarters in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: